English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The ongoing monitoring of the inpatient stage of treatment is the necessary condition for improving the quality of pharmacotherapy of such costly diseases as rheumatoid arthritis (RA) and optimizing the costs for its implementation. According to the data of 100 case histories of patients with RA the use of glucocorticoids (GCs), non-steroidal anti-inflammatory drugs (NSAIDs) and gastroprotective drug prevention of complications associated with their use at the inpatient stage of treatment has been analyzed, and compliance of prescriptions with the provisions of the updated national unified clinical protocol of 2014 (UCPMC RA), as well as the recommendations of the European League Against Rheumatism (EULAR) in taking GCs and NSAIDs for rheumatoid diseases has been identified. It was formulated that GCs for systemic use and NSAIDs were prescribed according to the regimens specified in UCPMC RA and in compliance with the algorithm of the rational choice of NSAIDs for RA. It was determined that for the levels of prescriptions of GCs and NSAIDs set the gastroprotective drug prevention of complications associated with their use in the rheumatology department was carried out properly and according to the recommendations of UCPMC RA and EULAR. A high level of compliance by practitioners of a healthcare institution with the provisions of the current UCPMC RA has been determined, and it will allow both preventing in advance possible undesired effects of using GCs and NSAIDs and reducing the costs of their correction.

The assessment of compliance of the inpatient stage pharmacotherapy when treating rheumatoid arthritis with provisions of industry standards